SSRIs and SNRIs for Hot Flashes: A Non-Hormonal Option

Yes. Certain SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) — medication classes better known for treating depression and anxiety — also reduce the frequency and severity of hot flashes and night sweats, collectively called vasomotor symptoms. Research shows they can cut hot flashes by as much as 65%, and unlike some other options they often start working within the first week. They became an important tool because not everyone can or wants to take hormones. For women who've had breast cancer, have a clotting history, or simply prefer to avoid HRT, SSRIs and SNRIs offer real relief through a completely different mechanism — they appear to influence the brain's temperature-regulation center rather than replacing estrogen. If you want to compare the full menu of options first, our overview of [hot flash causes and evidence-based treatments](/blog/hot-flashes-causes-triggers-and-evidence-based-treatments) puts these in context.

Several have solid evidence. Paroxetine showed the greatest overall reduction in one comparison — about 40.6% at 10 mg and 51.7% at 20 mg versus placebo — and its low-dose 7.5 mg form is FDA-approved for this use. Among SNRIs, venlafaxine (37.5 mg) had the fastest onset, with a 41% reduction by one week (about 26% better than placebo), though it can cause more nausea, dry mouth, and constipation. Desvenlafaxine reduced hot flashes by around 62% — roughly seven fewer episodes a day — and lessened severity by about 25%. Escitalopram and citalopram are also effective. Which one fits you depends on side-effect profile, other symptoms (an SSRI may help co-occurring anxiety), and any medications you already take. Notably, women on tamoxifen for breast cancer should avoid paroxetine, which can interfere with it — a reason individualized prescribing matters.

The MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) network ran some of the most rigorous trials on non-hormonal options. In a landmark study, low-dose venlafaxine was found to be nearly as effective as low-dose estradiol (a form of estrogen) for reducing vasomotor symptoms. Estradiol had a slight edge, but the difference was small enough that for many women an SNRI is a reasonable, effective alternative to hormones. Other MsFLASH work supported escitalopram as effective for hot flashes as well. The practical takeaway is important: you don't have to choose between "hormones" and "suffering." Non-hormonal medications have real, trial-backed efficacy — not as strong as full-dose HRT in every case, but often close, and clearly better than placebo. This gives women and clinicians genuine choice based on health history and preference.

Generally, the doses used to treat hot flashes are lower than those used for depression. Paroxetine for hot flashes is prescribed at 7.5 mg (Brisdelle), well below typical antidepressant doses, and venlafaxine is often started at 37.5 mg. Lower doses can mean fewer side effects while still delivering symptom relief, because the effect on temperature regulation doesn't require the higher doses that mood treatment sometimes does. That said, side effects can still occur — commonly nausea, dry mouth, headache, or reduced libido — and are usually mild and improve over the first couple of weeks. Importantly, you should not stop these medications abruptly; they need to be tapered under a doctor's guidance to avoid discontinuation symptoms. If you also have low mood, this is worth discussing openly — note that antidepressants aren't always the right tool for [menopause depression](/blog/menopause-depression-why-ssris-arent-always-the-answer), and the reasoning differs from hot flash treatment.

There's now a growing non-hormonal toolkit. Fezolinetant (Veozah) and elinzanetant (Lynkuet) are newer drugs in a class called NK3 receptor antagonists, which target the specific brain pathway (the KNDy neurons) that drives hot flashes. In trials these can be very effective and don't carry antidepressant-type side effects, but they're newer and often more expensive. SSRIs and SNRIs, by contrast, are inexpensive, widely available, decades-proven, and can pull double duty for anxiety or mood — which is common in menopause. The best choice depends on your symptoms, budget, and health history. For a deeper look at the newer agents, see our guides to [Veozah for hot flashes](/blog/veozah-fezolinetant-for-hot-flashes-2026-guide) and [Lynkuet (elinzanetant)](/blog/lynkuet-elinzanetant-non-hormonal-hot-flash-treatment). And if you're still weighing hormones, our guide on [when to start HRT](/blog/when-to-start-hrt-timing-and-the-window-of-opportunity) covers that path. Bring the options to your clinician to match one to you.